Also Highlight News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Also Highlight. Real-time updates on events, politics, business and more.

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

May 22, 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A...

United States Jean Pierre Sommadossi Jonae Barnes Qi Huang Alina Jucov Atea Pharmaceuticals Inc

Source: marketscreener.com

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-In-Class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis...

May 22, 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also H

United States Alina Jucov Qi Huang Jonae Barnes Jean Pierre Sommadossi Corporate Communications

Source: menafn.com

Allogene Therapeutics Announces Oral Presentation of Phase

March 14, 2023

Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint...

United States Zachary Roberts Barbra Sasu Samer Srour Allogene Allo Christine Cassiano

Source: globenewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Also Highlight News Today

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-In-Class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis...

Allogene Therapeutics Announces Oral Presentation of Phase

Explore More Categories